Search Medical Condition
Please enter condition
Please choose location

Hilliard, Ohio Clinical Trials

A listing of Hilliard, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (478) clinical trials

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency department visits. The way an individual processes a drug is in part determined by their genes, and ...

Phase N/A

0.0 miles

Learn More »

A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

This is an open-label, non‐randomized, multicenter Phase 1/2 study of MEDI4736 in subjects with recurrent, platinum-resistant ovarian cancer, scheduled to receive Pegylated Liposomal Doxorubicin (PLD). Subjects will be treated during each 28-day cycle according to the treatment schedule.

Phase

0.0 miles

Learn More »

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD or Pembrolizumab in Adults With FRa + Adv. EOC Primary Peritoneal Fallopian Tube or Endometrial Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

0.0 miles

Learn More »

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The ...

Phase

0.0 miles

Learn More »

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their ...

Phase

1.06 miles

Learn More »

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

The primary objective of the study is to evaluate the time to resolution of influenza symptoms in adults with acute uncomplicated seasonal influenza A following administration of VX-787, with and without concomitant oseltamivir.

Phase

1.06 miles

Learn More »

Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD

Phase

3.28 miles

Learn More »

Study of Suture Repair of Torn Meniscus in the Knee

Potential subjects will undergo Screening for eligibility based on Inclusion/Exclusion criteria. Screening will include an x-ray of the injured knee and evaluation of an MRI of the injured knee within 6 months prior to the scheduled procedure. During the procedure, the meniscal tear will be evaluated by arthroscopy to determine ...

Phase N/A

3.28 miles

Learn More »

Study of Ranolazine in Myotonia Congenita and Paramyotonia Congenita

Recent advances in the understanding of myotonia congenita have identified potential areas that could possibly respond to treatment in a drug study. The drug ranolazine (trade name Ranexa) is a FDA-approved medication to treat chest pain in patients with heart disease. Ranolazine has been studied in mice with myotonia congenita. ...

Phase

3.28 miles

Learn More »

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial ...

Phase

3.28 miles

Learn More »